Bottom line
FIJYX vs BIB: the short answer
FIJYX (Fidelity Advisor Biotechnology Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are both mutual funds.
But BIB is far broader, holding 267 positions to 129 for FIJYX, so beyond the top names it adds exposure FIJYX doesn't have.
FIJYX is cheaper at 0.57% vs 0.95% — a difference of $38 a year per $10,000 invested.
Over five years, FIJYX returned +8.1% a year vs −1.0% for BIB (reporting dates differ).
Updated Nov 19, 2026
FIJYX vs BIB side by side
| FIJYX | BIB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Fidelity | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.57% | 0.95% |
| Annual cost per $10k | $57 | $95 |
| 10-yr cost on $10k (prospectus) | $714 | $1,401 |
| Max front load | — | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +40.1% | +59.3% |
| 5-yr return (annualized) | +8.1% | −1.0% |
| 10-yr return (annualized) | — | +1.4% |
| Best quarter | +30.3% | +56.2% |
| Worst quarter | −27.8% | −42.7% |
| Net assets (fund) | $2.2B | $73.7M |
| Number of holdings | 129 | 267 |
| Portfolio turnover | 54% | 29% |
| Returns as of | Sep 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
9 of FIJYX's top 25 holdings also appear in BIB's top 25.
| Holding | FIJYX | BIB |
|---|---|---|
| Gilead Sciences Inc | 5.70% | 4.66% |
| Alnylam Pharmaceuticals Inc | 3.62% | 2.01% |
| Insmed Inc | 3.05% | 1.16% |
| Revolution Medicines Inc | 3.00% | 1.57% |
| Argenx Se | 3.00% | 1.19% |
| Biogen Inc | 2.71% | 1.44% |
| Amgen Inc | 2.37% | 4.48% |
| Moderna Inc | 1.60% | 0.94% |
| Vertex Pharmaceuticals Inc | 1.39% | 4.65% |
Source: SEC Form N-PORT
FIJYX top 10
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Dianthus Therapeutics Inc — 3.55%
- Cogent Biosciences Inc — 3.25%
- Oruka Therapeutics Inc — 3.24%
- Insmed Inc — 3.05%
- Revolution Medicines Inc — 3.00%
- Argenx Se — 3.00%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between FIJYX and BIB?
Which is cheaper, FIJYX or BIB?
Should I own both FIJYX and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.